Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 4, 2008, Pages 1346-1349

  Chen, Chen ^a   Dyck, Brian ^a   Fleck, Beth A ^a   Foster, Alan C ^b   Grey, Jonathan ^a   Jovic, Florence ^a   Mesleh, Michael ^a   Phan, Kasey ^a   Tamiya, Junko ^a   Vickers, Troy ^a   Zhang, Mingzhu ^a  

^a Neurocrine Bioscience   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Inhibitor; Milnacipran; Monoamine transporter; Norepinephrine; Pharmacophore; Serotonin; Structure activity relationship; Synthesis

Indexed keywords

ATOMOXETINE; DULOXETINE; FLUOXETINE; MILNACIPRAN; VENLAFAXINE;

AQUEOUS SOLUTION; ARTICLE; CONFORMATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; NUCLEAR MAGNETIC RESONANCE; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

ACETAMIDES; ALKYLATION; AMIDES; CYCLOPROPANES; INDOLES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 38949169845     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.01.011     Document Type: Article

References (20)

1. Iversen L. Br. J. Pharmacol. 147 (2006) S82
2. Runyon S.P., and Carroll F.I. Curr. Top. Med. Chem. 6 (2006) 1825
3. Stokes P.E., and Holtz A. Clin. Therapeut. 19 (1997) 1135
4. Gibson A.P., Bettinger T.L., Patel N.C., and Crismon M.L. Ann. Pharmacother. 40 (2006) 1134
5. Frampton J.E., and Plosker G.L. CNS Drugs 21 (2007) 581
6. Dierick M. Eur. Psychiatry 12 (1997) 307s
7. Bisserbe J.C. Int. Clin. Psychopharmacol. 17 (2002) S43
8. Puozzo C., Panconi E., and Deprez D. Int. Clin. Psychopharmacol. 17 (2002) S25
9. Stahl S.M., Grady M.M., Moret C., and Briley M. CNS Spectr. 10 (2005) 732
10. Mochizucki D. Hum. Psychopharmacol. 19 (2004) S15-9
11. Rooks D.S. Curr. Opin. Rheumatol. 19 (2007) 111
12. Leo R.J., and Brooks V.L. Curr. Opin. Investig. Drugs 7 (2006) 637
13. The calculated log D values are 1.2 for milnacipran and 3.3 for duloxetine using ACD software.
14. Puozzo C., Lens S., Reh C., Michaelis K., Rosillon D., Deroubaix X., and Deprez D. Clin. Pharmacokinet. 44 (2005) 977
15. Bonnaud B., Cousse H., Mouzin G., Briley M., Stenger A., Fauran F., and Couzinier J.P. J. Med. Chem. 30 (1987) 318
16. Roggen H., Kehler J., Stensbol T.B., and Hansen T. Bioorg. Med. Chem. Lett. 17 (2007) 2834
17. Shuto S., Ono S., Imoto H., Yoshii K., and Matsuda A. J. Med. Chem. 41 (1998) 3507
18. Owens M.J., Morgan W.N., Plott S.J., and Nemeroff C.B. J. Pharmacol. Exp. Ther. 283 (1997) 1305
19. Kazuta Y., Tsujita R., Yamashita K., Uchino S., Kohsaka S., Matsuda A., and Shuto S. Bioorg. Med. Chem. 10 (2002) 3829
20. 11 buffer (pH = 7.0), and water suppression was accomplished using Excitation Sculpting with Gradients. Protons 16 and 18 were assigned from chemical shifts and multiplicities. Protons 15 and 17 were assigned based on correlations in COSY. Protons 7-11 were assigned from absolute value COSY. Protons 1, 2, and 4 were assigned from chemical shift and COSY correlations. The overlap of one proton from 1 and the proton 2 is confirmed via the HSQC experiment, which clearly shows two different carbons with the similar proton chemical shift.